去纤苷治疗肝小静脉闭塞病患者的效果

Defibrotide sodium () is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects. Defibrotide can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells.

Sodium defibrotide (defibrotide) is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). How effective is defibrotide in treating patients with hepatic veno-occlusive disease?

The following are two clinical trials compiled by the editor of Medical Partner Travel, which respectively analyzed the effect of defibrotide in the treatment of patients with hepatic veno-occlusive disease and children.

In one study, 19 patients with sHVOD were given 5 to 60 mg/kg of defibrotide sodium (defibrinoside) as intravenous infusion every day. The median use time was 15 days (2 to 61 days). In this study, a total of 42% of patients achieved complete response (CR), and the overall survival (OS) rate at 100 days after transplantation was 32%. Not only that, defibrinated sodium is also better tolerated by patients. Since then, multiple clinical trials have confirmed the effectiveness of defibrotide in the treatment of hepatic veno-occlusive disease.

In a clinical trial on the treatment of HVOD in children, the complete response (CR) rate using defibrotide () was 76%, and the overall survival (OS) rate 1,00 days after transplantation was 64%. The effect is very significant. Not only can defibrinated sodium be used to treat adults, children can also benefit from it.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: